Comparison of restenosis rate with sirolimus-eluting stent in STEMI patients with and without diabetes at 6-month angiographic follow-up.
Patients with diabetes mellitus (DM) are at high risk for restenosis after coronary stenting. However, whether drug-eluting stents are effective in diabetic patients presenting with ST-segment elevation myocardial infarction (STEMI) is uncertain. We report on a series of patients with or without DM followed up for 6 months after sirolimus-eluting stent implantation. This cohort study enrolled 195 STEMI patients who underwent sirolimus-eluting stent implantation and accepted angiographic followup at 6 months. There were no significant differences between the two groups in baseline clinical characteristics and risk factors. The two groups were treated with similar stent lengths and diameters. The unadjusted in-stent restenosis was significantly higher in diabetic than in non-diabetic patients at 6 months (7.8 vs. 1.7, P < 0.05). Multivariate analysis showed that only diabetes and current smoking were independent predictors of restenosis (odds ratio 12.82 and 7.98, respectively, both P < 0.05). The present study demonstrated that diabetes increased restenosis after sirolimus-eluting stent placement in STEMI patients. This finding implicates that diabetes remains an important predictor for restenosis in the DES era.